ifosfamide has been researched along with Ventricular Dysfunction in 1 studies
Ventricular Dysfunction: A condition in which HEART VENTRICLES exhibit impaired function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)." | 7.83 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016) |
| "Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)." | 3.83 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwartz, CL | 1 |
| Wexler, LH | 1 |
| Krailo, MD | 1 |
| Teot, LA | 1 |
| Devidas, M | 1 |
| Steinherz, LJ | 1 |
| Goorin, AM | 1 |
| Gebhardt, MC | 1 |
| Healey, JH | 1 |
| Sato, JK | 1 |
| Meyers, PA | 1 |
| Grier, HE | 1 |
| Bernstein, ML | 1 |
| Lipshultz, SE | 1 |
1 other study available for ifosfamide and Ventricular Dysfunction
| Article | Year |
|---|---|
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotonic Agents; Chil | 2016 |